Position of the Transparency Council – Abrysvo respiratory syncytial virus vaccine (bivalent, recombinant)

At its meeting on 12 November 2024, the Transparency Council adopted position No. 119/2024 on the evaluation of the drug Abrysvo respiratory syncytial virus vaccine (bivalent, recombinant) for the indication: active immunization of persons 60 years of age and older.

Publication of the position >>